Objectives: Aim of this study was to analyze the feasibility of oncological treatment in pediatric patients belonging to Jehovah’s Witnesses and to describe the changing policy in performing transfusions and supportive care measures at two German pediatric cancer institutions. Patients and Methods: Over a period of 16 years 21 treatments according to the current cooperative protocols were performed in 14 children of Jehovah’s Witnesses. Various hematological supportive care measures such as supplementation with iron, human erythropoietin, interleukin 11, granulocyte colony-stimulating factor and autologous or allogeneic stem cell rescue had been applied. For comparison matched pairs treated in our hospitals not belonging to Jehovah’s Witnesses and 50 pediatric and adult oncological patients belonging to Jehovah’s Witnesses reviewed from the international literature were analyzed with respect to transfusions and outcome. Results: So far, 9 of 14 children are surviving 16–195 months (median 26 months). During the primary therapy they received markedly less transfusions than the control cohort (–39,1% red blood cell transfusions and –37,5% platelet transfusions). The review of 50 reported cases showed that oncological therapy can also be successfully performed with a restricted transfusion regimen in children and particularly in adults. Conclusion: Pediatric cancer patients belonging to Jehovah’s Witnesses can be treated similarly to other patients. A restrictive transfusion policy and the broad application of hematopoietic supportive care measures may reduce transfusions. This treatment policy and a continuous collaboration with the Hospital Liaison Committee for Jehovah’s Witnesses appears to create an oncological treatment situation with a high compliance of patients and parents where court orders may not be necessary.

This content is only available via PDF.
© 2004 S. Karger GmbH, Freiburg
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.